Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
Login Archives Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
    ×
  • Subscribe
Enter stock ticker or keyword
×
Join 100,000+ Like-Minded Investors Today
Twitter

Ebola stocks

  • Featured Story

    This Big-Cap "Ebola Stock" Is Also a Dividend Aristocrat

    Ebola stock

    By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - November 7, 2014

    Over the past few weeks, one "clinical stage" pharma firm after another has seen its stock price rise and plummet on rumors about who has the most likely Ebola vaccine.

    I'm not taking you on any wild rides like that. Instead, check out this solid big-cap company that's gearing up for a major Ebola drug trial.

    Now, before the crowd notices, let's take a look - this is not your typical "Ebola stock"...

Article Index

  • This Big-Cap "Ebola Stock" Is Also a Dividend Aristocrat
  • More than an "Ebola Stock" - This Medical Leader Is a Long-Term Profit Machine
  • Ebola Stocks Surge as Race for Treatment Heats Up - but Steer Clear of Overhyped Plays
  • How Close Is Tekmira Pharma (Nasdaq: TKMR) to an Ebola Treatment?
  • Ignore "Ebola Stocks" Hype - This Medical Tech Leader Is Already Set Up to Treat the Next Major Outbreak

This Big-Cap "Ebola Stock" Is Also a Dividend Aristocrat

By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - November 7, 2014

Ebola stock

Over the past few weeks, one "clinical stage" pharma firm after another has seen its stock price rise and plummet on rumors about who has the most likely Ebola vaccine.

I'm not taking you on any wild rides like that. Instead, check out this solid big-cap company that's gearing up for a major Ebola drug trial.

Now, before the crowd notices, let's take a look - this is not your typical "Ebola stock"...

More than an "Ebola Stock" - This Medical Leader Is a Long-Term Profit Machine

By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM - October 15, 2014

ebola stock

For weeks, investors have been chasing one "Ebola stock" after another, hoping to find the company with a cure for the disease.

But these investors are going about it all wrong. Instead of finding sound investments, they're just chasing headlines.

Now, Money Morning experts have found a long-term profit play that’s also benefitting from the short-term Ebola news…

Ebola Stocks Surge as Race for Treatment Heats Up - but Steer Clear of Overhyped Plays

By Diane Alter, Contributing Writer, Money Morning - October 7, 2014

Ebola Stocks

The number of companies racing to find an Ebola treatment is increasing. All drugs remain in the testing stage, but that hasn't stopped investors from piling into these "Ebola stocks."

Chimerix (Nasdaq: CMRX) climbed 5% Monday on reports that the Ebola patient in Dallas is being treated with its drug, brincidofovir.

Read More…

How Close Is Tekmira Pharma (Nasdaq: TKMR) to an Ebola Treatment?

By Diane Alter, Contributing Writer, Money Morning - October 1, 2014

how close is Tekmira to an Ebola treatment

Tekmira Pharma (Nasdaq: TKMR) stock surged more than 25% to $26.50 Wednesday after the CDC confirmed Tuesday the first Ebola diagnosis in the United States - and the first outside of Africa.

But just how close is Tekmira to getting approval for an Ebola treatment?

Here's a closer look at whether the Tekmira vaccine is the answer everyone hopes it is...

Ignore "Ebola Stocks" Hype - This Medical Tech Leader Is Already Set Up to Treat the Next Major Outbreak

By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report - August 20, 2014

ebola stocks

The first U.S. case of the deadly Ebola virus has been confirmed in a patient in Dallas, Texas, and the news sent "Ebola stocks" - the companies racing to get approval for treatment - up as much as 20% in after-hours trading Tuesday.

But instead of trying to guess which company is going to come through with a cure, I recommend you concentrate on companies making the best medical testing, diagnosis, and drug delivery systems.

Like this one – it’s going to power sharply higher in the next 12 months…

QUICK LINKS
About Us How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Login to Private Briefing

© 2022 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles Street | Baltimore, MD 21201 | USA | Phone: 888.384.8339 I Disclaimer | Sitemap | Privacy Policy | Whitelist Us